No annual revenue total was found in Acumen Pharmaceuticals, Inc.'s SEC filings.
Acumen Pharmaceuticals, Inc. (ABOS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$115.6 million. As of Sep 30, 2026 it held $78.6 million in cash and investments and $46.7 million in total debt.
Revenue
—
Net income (TTM)
$-103.96M
+22.0% vs year-ago TTM
Operating cash flow (TTM)
$-87.95M
+28.9% vs year-ago TTM
Free cash flow (TTM)
$-87.95M
+28.9% vs year-ago TTM
EPS (TTM)
$-1.55
+29.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
72.21M
+19.2% vs prior year
Net cash
$31.89M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ABOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1576885
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$123.8M | -$114.0M | -$61.1M | -$45.2M | -$19.6M |
| Net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M | -$100.6M |
| Diluted EPS | -$2.00 | -$1.71 | -$1.08 | -$1.06 | — |
| Operating cash flow | -$115.5M | -$86.2M | -$43.1M | -$35.2M | -$18.0M |
| Free cash flow | -$115.6M | -$86.2M | -$43.1M | -$35.3M | -$18.0M |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M |
| Stockholders' equity | $70.4M | $181.8M | $267.0M | $188.8M | $225.2M |
| Cash and investments | $116.9M | $231.5M | $306.1M | $63.3M | $225.9M |
| Total debt | $40.1M | $29.7M | $31.0M | $105,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 30, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Oct 26, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
All 364 Acumen Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.